Retatrutide

This is a triple agonist medication developed by Eli Lilly, designed to aid in weight loss by targeting multiple pathways. It distinguishes itself by showing promising results in recent clinical trials, with participants experiencing an average weight loss of up to 24.2%. The medication is primarily targeted at individuals seeking significant weight reduction through pharmaceutical intervention.